Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim R Cressey

Showing results (11-20 of 166) with videos related to

Pageof 17
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|June 1, 2014
The role of formulation on the pharmacokinetics of antiretroviral drugsDiane E T Bastiaans, Tim R Cressey, Herman Vromans, et al.
Antimicrobial Agents and Chemotherapy|July 4, 2007
Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patientsTim R Cressey, Sawitree Nangola, Yardpiroon Tawon, et al.
The Pediatric Infectious Disease Journal|December 8, 2011
Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuationWasana Prasitsuebsai, Tim R Cressey, Edmund Capparelli, et al.
The American Journal of Tropical Medicine and Hygiene|September 30, 2015
Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai AdultsSiwalee Rattanapunya, Tim R Cressey, Ronnatrai Rueangweerayut, et al.
Malaria Journal|October 11, 2015
Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adultsSiwalee Rattanapunya, Tim R Cressey, Ronnatrai Rueangweerayut, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 11, 2025
Brief Report: Can a Fraction of the Dolutegravir Dispersible Tablet Solution be Used to Dose Neonates?Cassius M Phogole, Adrie Bekker, Tim R Cressey, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 1, 2006
Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapyTim R Cressey, Prattana Leenasirimakul, Gonzague Jourdain, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2012
Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavirKulkanya Chokephaibulkit, Maneeratn Nuntarukchaikul, Wanatpreeya Phongsamart, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 23, 2020
Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV)Adrie Bekker, Eric H Decloedt, Gretchen Slade, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2020
Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatmentQuanhathai Kaewpoowat, Romanee Chaiwarith, Saowaluck Yasri, et al.
Pageof 17

Showing results (11-20 of 166) with videos related to

Sort By:
Pageof 17
Expert Opinion on Drug Metabolism & Toxicology|June 1, 2014
The role of formulation on the pharmacokinetics of antiretroviral drugsDiane E T Bastiaans, Tim R Cressey, Herman Vromans, et al.
Antimicrobial Agents and Chemotherapy|July 4, 2007
Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patientsTim R Cressey, Sawitree Nangola, Yardpiroon Tawon, et al.
The Pediatric Infectious Disease Journal|December 8, 2011
Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuationWasana Prasitsuebsai, Tim R Cressey, Edmund Capparelli, et al.
The American Journal of Tropical Medicine and Hygiene|September 30, 2015
Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai AdultsSiwalee Rattanapunya, Tim R Cressey, Ronnatrai Rueangweerayut, et al.
Malaria Journal|October 11, 2015
Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adultsSiwalee Rattanapunya, Tim R Cressey, Ronnatrai Rueangweerayut, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 11, 2025
Brief Report: Can a Fraction of the Dolutegravir Dispersible Tablet Solution be Used to Dose Neonates?Cassius M Phogole, Adrie Bekker, Tim R Cressey, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 1, 2006
Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapyTim R Cressey, Prattana Leenasirimakul, Gonzague Jourdain, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2012
Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavirKulkanya Chokephaibulkit, Maneeratn Nuntarukchaikul, Wanatpreeya Phongsamart, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 23, 2020
Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV)Adrie Bekker, Eric H Decloedt, Gretchen Slade, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2020
Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatmentQuanhathai Kaewpoowat, Romanee Chaiwarith, Saowaluck Yasri, et al.
Pageof 17